2018年转移性透明细胞肾细胞癌的系统治疗:当前范式、免疫治疗的应用及未来方向
VEGF酪氨酸激酶抑制剂单药曾是标准治疗,现正与ICI联合用于一线;CheckMate-214研究显示ICI在中等/低危患者中带来总生存获益,已成为标准治疗。联合ICI方案可能成为下一个标准治疗。
要点
- VEGF TKI单药曾是标准治疗,现与ICI联合用于一线。
- CheckMate-214显示ICI在中等/低危患者中总生存获益,已成为标准。
- 卡博替尼在中等/低危患者中PFS优于舒尼替尼。
核心结论
- 自VEGF抑制剂引入以来,mccRCC治疗格局已演变。
- 涉及检查点抑制剂的联合治疗可能成为下一个标准治疗。
研究设计与样本
- 系统检索PubMed/Medline、Embase、Web of Knowledge和Cochrane Library至2018年2月,遵循PRISMA声明,进行叙述性综述。
主要发现
- VEGF TKI单药曾是标准治疗,现一线与ICI联合使用。
- 卡博替尼在中等和低危患者(IMDC标准)中PFS优于舒尼替尼。
- mTOR治疗很大程度上劣于VEGF靶向治疗,但在联合策略中有作用。
- 细胞因子在大多数地区已被取代,疫苗在III期研究中未显示生存改善。
- CheckMate-214显示ICI在未治疗的中等/低危患者中总生存获益,已成为标准治疗;IMmotion 151生存数据尚未成熟。
关键数值与推荐
- VEGF TKI单药治疗:9项研究。
- mTOR抑制剂:2项研究。
- 细胞因子:3项研究。
- 疫苗:3项研究。
- ICI:9项研究。
临床怎么用
- 未治疗的中等/低危mccRCC患者应接受ICI联合治疗。
- 卡博替尼可用于中等/低危患者的一线治疗。
- mTOR抑制剂不推荐作为单药首选,但可考虑联合策略。
- 细胞因子和疫苗已非当前主流实践。
局限性
- IMmotion 151的生存数据尚未成熟。
- 多项III期联合试验正在进行,结果待读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has greatly evolved over the last 15yr. More recently, combination strategies involving contemporary immunotherapy have emerged as key opportunities to further shift the treatment landscape. OBJECTIVE: To review the evidence regarding the efficacy and safety of standard therapeutic options in mccRCC as well as combination immunotherapy options on the horizon. EVIDENCE ACQUISITION: PubMed/Medline, Embase, Web of Knowledge, and Cochrane Library databases were searched up to February 2018 and according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. A narrative review of studies was performed. EVIDENCE SYNTHESIS: Twenty-six studies were included regarding therapies for metastatic RCC including vascular endothelial growth factor (VEGF)-directed therapy (n=9), mTOR inhibitors (n=2), cytokines (n=3), vaccines (n=3), and immune checkpoint inhibitors (ICIs, n=9). VEGF tyrosine kinase inhibitor monotherapy had been the standard therapy, and its use is evolving in the front-line setting with ICIs; cabozantinib provides superior progression-free survival versus sunitinib in intermediate- and poor-risk patients, by International Metastatic RCC Database Consortium criteria. The mTOR therapy is largely inferior to VEGF-directed therapy, although it has a role in combination strategies. Cytokines have largely been replaced in current practice throughout most regions, and vaccines have failed to show improved survival in phase III studies to date. ICIs have now become standard care in untreated patients with intermediate and poor risks, given overall survival benefit seen with CheckMate-214 study; survival data from IMmotion 151 are not yet mature. Several ongoing phase III combination trials, with promising early-phase data, are due to be read out. CONCLUSIONS: The treatment landscape for mccRCC has evolved since the introduction of VEGF inhibitors. Combination therapies involving checkpoint inhibitors could be the next standard of care. PATIENT SUMMARY: With the expanding role of immune checkpoint inhibitors in metastatic renal cell carcinoma, the treatment paradigm has shifted to include combination therapy in the untreated setting. As the field advances, the bar has been raised in evaluating ongoing combination strategies.
引用
- Lalani AA, McGregor BA, Albiges L, et al. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. Eur Urol. 2018. PMID: 30327274. doi:10.1016/j.eururo.2018.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。